<DOC>
	<DOCNO>NCT02962531</DOCNO>
	<brief_summary>An open-label , randomize , three-period , three-way crossover trial single dose IX-01 12 healthy male subject . In period , subject receive single oral dose 1600 mg IX-01 , either aqueous dispersion fast state , caplets feed fast state</brief_summary>
	<brief_title>Relative Bioavailability Study IX-01 Caplet Versus Aqueous Dispersion Food Effect Caplet Healthy Males</brief_title>
	<detailed_description>This Relative Bioavailability Study compare single oral dos 1600mg IX-01 , either aqueous dispersion fast state , caplets feed fast state . Each volunteer study receive formulation list . Each formulation separate least 5-day drug-free ( washout ) period . - Treatment A : A single 1600 mg ( 4 x 400 caplets ) oral dose IX-01 fast condition - Treatment B : A single 1600 mg ( 4 x 400 caplets ) oral dose IX-01 fed condition - Treatment C : A single 1600 mg aqueous dispersion ( 20 mL ) oral dose IX-01 fast condition . In fasted treatment period , dose follow overnight fast least 10 hour . In fed treatment period , follow overnight fast least 10 hour , standard high-calorie , high-fat breakfast meal give 30 minute prior administration study drug . There final follow-up visit 7-10 day final dose study medication .</detailed_description>
	<criteria>Body mass index 18 30 kg/m2 Body weight Ëƒ60 kg ( 132 lb ) screen Able understand nature trial hazard participate . Ability communicate satisfactorily investigator participate , comply requirement entire trial Willing comply contraception requirement trial Willing give write consent participate Willing able remain study unit entire duration confinement period return outpatient visit Willing able consume entire highcalorie , highfat breakfast meal designate timeframe require fed study period Vital sign screen baseline within : heart rate : 5090 beat per minute ; systolic blood pressure : 100130 mmHg ; diastolic : 6090 mmHg Clinically relevant abnormal history , physical finding , ECG , laboratory value screen could interfere objective trial safety volunteer , include follow : Lipid and/or liver function test result &gt; 1.25 time upper limit normal another clinical laboratory result judge clinically significant An international normalised ratio &gt; 1.2 platelet count &lt; 150 x10^3/mL History unexplained syncope Family history unexplained sudden death sudden death due long QT syndrome QTcF interval &gt; 450 msec screen Bundle branch block another conduction abnormality ECG , mild first degree atrioventricular block , judge clinically significant Irregular rhythm ECG , sinus arrhythmia occasional supraventricular ectopic beat , judge clinically significant Twave configuration insufficient quality determination QT interval , assess ECG judge clinically significant Investigator Presence acute chronic illness history chronic illness sufficient invalidate participation trial make study participation unnecessarily hazardous Impaired gastrointestinal , endocrine , thyroid , hepatic , cardiovascular , respiratory , hematological , renal neurological function , diabetes mellitus , coronary heart disease , history psychotic mental illness Surgery ( e.g . stomach bypass ) medical condition might affect absorption , metabolism , elimination medicine Presence history severe adverse reaction drug and/or history skin reaction ( rash ) drug Previous allergic response involve hive , swell , shortness breath , anaphylaxis Has use overthecounter medication , nutritional dietary supplement , herbal preparation , vitamin , except short course medication ( acetaminophen ) , could interfere subject safety integrity trial data within 7 day prior first dose medication Any prescription medication within 14 day prior first dose study medication Participation another clinical trial within 60 day prior first dose study medication Previous participation trial clinical trial oxytocin receptor antagonist Presence history drug alcohol abuse , intake 21 unit alcohol weekly 5 cigarette daily Unwilling unable comply protocol requirement Positive urine screen drug abuse Positive hepatitis B surface antigen , hepatitis C antibody Human Immunodeficiency Virus screen previously treat hepatitis B , hepatitis C , Human Immunodeficiency Virus infection Donated blood plasma within 30 day prior first dose study medication Employee investigator site company involve sponsoring , organize , conduct trial , immediate family employee</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>